 Tianhong Li
|
|
| Title(s) | ASSOC PROF OF CLIN-HCOMP, Hematology and Oncology |
|---|
| Phone | 916-734-3772 |
|---|
| vCard | Download vCard |
|---|
|
|
 Bibliographic
-
Li T, Ma W, Tian EC. Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC. Chin Clin Oncol. 2018 Nov 09. PMID: 30525756.
-
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. PMID: 27919627.
-
Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016 Mar 10; 9:23. PMID: 26966027; PMCID: PMC4786998.
|
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
|